AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

AstraZeneca PLC (LON:AZN) has received a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is £153.33.

AZN has been the topic of several research reports. Citigroup boosted their price target on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a report on Friday, April 10th. Berenberg Bank upped their target price on AstraZeneca from £145 to £160 and gave the company a “buy” rating in a report on Tuesday, January 27th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a report on Wednesday. Finally, Shore Capital Group reiterated a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th.

AstraZeneca Stock Performance

LON:AZN opened at £136.12 on Thursday. The stock has a market cap of £211.10 billion, a P/E ratio of 20.50, a price-to-earnings-growth ratio of 0.86 and a beta of 0.22. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66. The stock’s 50-day moving average is £145.94 and its 200-day moving average is £140.01. AstraZeneca has a 1-year low of GBX 9,651 and a 1-year high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.